GW842166X Alleviates Osteoarthritis by Repressing LPS-mediated Chondrocyte Catabolism in Mice

Abstract

Objective

To explore the role and underlying mechanism of GW842166X on osteoarthritis and osteoarthritis-associated abnormal catabolism.

Methods

The extracted mouse chondrocytes were treated with GW842166X followed by lipopolysaccharide (LPS). The chondrocytes were divided into the control group, LPS group, LPS+50 nmol/L GW842166X group, and LPS+100 nmol/L GW842166X group. The cytotoxicity of GW842166X was tested using the CCK-8 assay. Western blot, RT-qPCR, and ELISA were applied to evaluate the expression of the inflammatory biomarkers in mouse chondrocytes. The expression of extracellular matrix molecules was detected by the Western blot, RT-qPCR, and immunofluorescence. Additionally, the activity of NF-κB was checked by the Western blot and immunofluorescence. The mouse Hulth models were generated to examine the in vivo effects of GW842166X on osteoarthritis. Hematoxylin and eosin staining, safranin O/fast green staining, and immunohistochemistry were applied to detect the histological changes.

Results

GW842166X below 200 µmol/L had no cytotoxicity on the mouse chondrocytes. LPS-induced high expression of TGF-β1, IL-10, TNF-α, and IL-6 was significantly reduced by GW842166X. In addition, GW842166X upregulated the expression of aggrecan and collagen type III, which was downregulated after the LPS stimulation. The upregulated expression of ADAMTS-5 and MMP-13 by LPS stimulation was dropped in response to the GW842166X treatment. Furthermore, LPS decreased the IκBα expression in the cytoplasm and increased the nuclear p65 expression. However, these changes were reversed by the GW842166X pretreatment. Moreover, the damages in the knees caused by the Hulth surgery in mice were restored by GW842166X.

Conclusion

GW842166X impeded the LPS-mediated catabolism in mouse chondrocytes, thereby inhibiting the progression of osteoarthritis.

Keywords

GW842166X / lipopolysaccharide / osteoarthritis / chondrocyte catabolism / cartilage / extracellular matrix

References

[1] HunterDJ, MarchL, ChewM. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet, 2020, 396(10264): 1711-1712

[2] XieY, ZinkleA, ChenL, et al.. Fibroblast growth factor signalling in osteoarthritis and cartilage repair. Nat Rev Rheumatol, 2020, 16(10): 547-564

[3] LatourteA, KloppenburgM, RichetteP. Emerging pharmaceutical therapies for osteoarthritis. Nat Rev Rheumatol, 2020, 16(12): 673-688

[4] SharmaL. Osteoarthritis of the Knee. N Engl J Med, 2021, 384(1): 51-59

[5] ZhengL, ZhangZ, ShengP, et al.. The role of metabolism in chondrocyte dysfunction and the progression of osteoarthritis. Ageing Res Rev, 2021, 66: 101249

[6] ChoiMC, JoJ, LeeM, et al.. Intra-Articular Administration of Cramp into Mouse Knee Joint Exacerbates Experimental Osteoarthritis Progression. Int J Mol Sci, 2021, 22(7): 3429

[7] HashimotoM, NakasaT, HikataT, et al.. Molecular network of cartilage homeostasis and osteoarthritis. Med Res Rev, 2008, 28(3): 464-481

[8] WuQ, MaY, LiuY, et al.. CB2R agonist JWH-133 attenuates chronic inflammation by restraining M1 macrophage polarization via Nrf2/HO-1 pathway in diet-induced obese mice. Life Sci, 2020, 260: 118424

[9] AliAM, El-TawilOS, Al-MokaddemAK, et al.. Promoted inhibition of TLR4/miR-155/NFkB p65 signaling by cannabinoid receptor 2 agonist (AM1241), aborts inflammation and progress of hepatic fibrosis induced by thioacetamide. Chem Biol Interact, 2021, 336: 109398

[10] YaoBB, HsiehGC, FrostJM, et al.. In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol, 2008, 153(2): 390-401

[11] GiblinGM, O’ShaughnessyCT, NaylorA, et al.. Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. J Med Chem, 2007, 50(11): 2597-2600

[12] SenR, BaltimoreD. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell, 1986, 46(5): 705-716

[13] XuZ, ShenZH, WuB, et al.. Small molecule natural compound targets the NF-kappaB signaling and ameliorates the development of osteoarthritis. J Cell Physiol, 2021, 236(11): 7298-7307

[14] SafiriS, KolahiAA, SmithE, et al.. Global, regional and national burden of osteoarthritis 1990–2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis, 2020, 79(6): 819-828

[15] OstenfeldT, PriceJ, AlbaneseM, et al.. A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction. Clin J Pain, 2011, 27(8): 668-676

[16] AyralX, DougadosM, ListratV, et al.. Arthroscopic evaluation of chondropathy in osteoarthritis of the knee. J Rheumatol, 1996, 23(4): 698-706

[17] LiYS, XiaoWF, LuoW. Cellular aging towards osteoarthritis. Mech Ageing Dev, 2017, 162: 80-84

[18] Astephen WilsonJL, KobsarD. Osteoarthritis year in review 2020: mechanics. Osteoarthritis Cartilage, 2021, 29(2): 161-169

[19] CaronMMJ, JanssenMPF, PeetersL, et al.. Aggrecan and COMP Improve Periosteal Chondrogenesis by Delaying Chondrocyte Hypertrophic Maturation. Front Bioeng Biotechnol, 2020, 8: 1036

[20] ZhengG, ZhanY, TangQ, et al.. Monascin inhibits IL-1beta induced catabolism in mouse chondrocytes and ameliorates murine osteoarthritis. Food Funct, 2018, 9(3): 1454-1464

[21] ZhouF, MeiJ, HanX, et al.. Kinsenoside attenuates osteoarthritis by repolarizing macrophages through inactivating NF-kappaB/MAPK signaling and protecting chondrocytes. Acta Pharm Sin B, 2019, 9(5): 973-985

[22] De SantaF, VitielloL, TorcinaroA, et al.. The Role of Metabolic Remodeling in Macrophage Polarization and Its Effect on Skeletal Muscle Regeneration. Antioxid Redox Signal, 2019, 30(12): 1553-1598

[23] ZhenG, WenC, JiaX, et al.. Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med, 2013, 19(6): 704-712

[24] WangT, HeC. Pro-inflammatory cytokines: The link between obesity and osteoarthritis. Cytokine Growth Factor Rev, 2018, 44: 38-50

[25] IannoneF, LapadulaG. The pathophysiology of osteoarthritis. Aging Clin Exp Res, 2003, 15(5): 364-372

[26] LiuJ, LiuS, PanW, et al.. Wogonoside attenuates the articular cartilage injury and the infiltration of Th1/Th2-type cytokines in papain-induced osteoarthritis in rat model via inhibiting the NF-kappaB and ERK1/2 activation. Immunopharmacol Immunotoxicol, 2021, 43(3): 343-352

[27] ArraM, SwarnkarG, KeK, et al.. LDHA-mediated ROS generation in chondrocytes is a potential therapeutic target for osteoarthritis. Nat Commun, 2020, 11(1): 3427

[28] DongN, LiX, XueC, et al.. Astragalus polysaccharides alleviates LPS-induced inflammation via the NF-kappaB/MAPK signaling pathway. J Cell Physiol, 2020, 235(7–8): 5525-5540

[29] KnightsAJ, YangL, ShahM, et al.. Kruppel-like factor 3 (KLF3) suppresses NF-kappaB-driven inflammation in mice. J Biol Chem, 2020, 295(18): 6080-6091

[30] FanMP, SiM, LiBJ, et al.. Cell therapy of a knee osteoarthritis rat model using precartilaginous stem cells. Eur Rev Med Pharmacol Sci, 2018, 22(7): 2119-2125